Eight different compounds, all nucleoside analogues, could presently be considered as
potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic …

Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent
RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved …

Remdesivir (GS-5734) is a 1′-cyano-substituted adenosine nucleotide analogue prodrug
that shows broad-spectrum antiviral activity against several RNA viruses. This compound is …

Annual and sporadic influenza outbreaks pose a great threat to human health and the
economy worldwide. Moreover, the frequent mutation of influenza viruses caused by antigen …

Abstract Background Non-pharmaceutical interventions (NPIs), such as sanitary measures
and travel restrictions, aimed at controlling the severe acute respiratory syndrome …

In the past two decades, three highly pathogenic human coronaviruses severe acute
respiratory syndrome coronavirus (SARS‐CoV), Middle East respiratory syndrome …

Influenza A viruses possess a high antigenic shift, and the approved anti-influenza drugs are
extremely limited, which makes the development of novel anti-influenza drugs for the clinical …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the complicated
disease COVID-19. Clinicians are continuously facing huge problems in the treatment of …

Purpose Respiratory syncytial virus (RSV) and influenza are important viral pathogens
worldwide. Children, in particular, bear considerable burdens of morbidity and mortality …

We quantified the effects of adherence to various non-pharmaceutical interventions (NPIs)
on the seasonal influenza epidemic dynamics in Japan during 2020. The total monthly …